More and more women are investing in medtech startups as the next phase of their professional development. 

It's a key career move that can fuel further business growth while establishing women entrepreneurs as experts and investors to be taken seriously.

But all investors need to know what to look for when gauging a pitch from a startup, because it's not just about the cool new science or the revenue projections. 

My friend and mentor Faz Bashi taught me a thing or two about investing, and has been working to educate and empower other women looking to take this important professional step.

Empowering Female Entrepreneurs and Investors with Faz Bashi

Whether you are an investor or inventor/founder, there are some things you need to avoid if you want your FDA submission to succeed, some common regulatory mistakes that a lot of startups make. 

These common misconceptions about the FDA submission process can cost you time and money and extend your go-to-market timeline, so it's worth knowing how to avoid them.

The FDA No Good Very Bad Day: Common Regulatory Mistakes

It used to be that Europe was the first choice when bringing a product to market. Relaxed regulation meant a quick approval and the chance to earn some money while waiting for FDA approval. That's not the case anymore, and thanks to MDR, there are new challenges and roadblocks - not to mention a LOT more expense - involved in bringing a medical device to market in Europe.

The MDR No Good Very Bad Day: Go To Market Challenges in the EU

We all knew that MDR would change the medical device industry forever, hopefully for the better. But as manufacturers grapple with redundant requirements and notified bodies struggle to attract and retain the qualified staff mandated by the new regulation, it becomes clear that MDR is not just changing the medical device industry - it's requiring an entirely new mindset.

EUDAMED, MDR and Other Madness with Richard Houlihan - Part I

This is the second part of my conversation with Richard Houlihan, where we delve into the current status of the EUDAMED database, the intricacies of the data entry process, and why the EU competent authorities are not your friends.

EUDAMED, MDR and Even More Madness with Richard Houlihan

It's no longer a secret that MDR has morphed into an unmitigated disaster for the medical device industry - and Michelle has the goods to prove it. In this first in a series, she spills the beans on notified body readiness, the roadblocks that have been causing the most trouble, and the FDA's long-term plan to become the easier pathway to market.

The Aftermath of MDR - Part I

Six months into MDR and manufacturers and notified bodies are clashing over differences in opinion and fighting over their respective interpretation of the standards in pursuit of product certification.

In this second installment of a series, I share three real-world examples of what actual clients faced when going through the MDR certification process.

You'll want to listen and learn from their experiences, so you'll be better prepared for your boxing match with your notified body.

The Aftermath of MDR - Part II

In this final segment from 𝗧𝗵𝗲 𝗔𝗳𝘁𝗲𝗿𝗺𝗮𝘁𝗵 𝗼𝗳 𝗠𝗗𝗥 webinar, we discuss what you should and should not do when preparing for your certification, then segue into what you need to consider when building the business case for (or against) pursuing certification.



This one runs a bit longer than 15 minutes because it includes most of the Q+A session, and that has some juicy tidbits you don't want to miss.

The Aftermath Of MDR - Part III

You've developed a novel technology and want to bring it to market in the US. Now what? Can you submit as a breakthrough device, or is the de novo route a better choice? How are they different? How are they similar? 

Breathe - and listen in as Michelle walks you through the options.

The Aftermath of MDR - Part II

RAQA Today